DOXORUBICIN
B-Cell Childhood Acute Lymphoblastic Leukemia
Children's Oncology GroupSmall moleculePhase 3Dormant
BBB
76/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 67/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the B-Cell Childhood Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE St. Jude Children's Research Hospital | Phase 3 | A |
PEGASPARGASE St. Jude Children's Research Hospital | Phase 3 | A |
MERCAPTOPURINE ANHYDROUS St. Jude Children's Research Hospital | Phase 3 | A |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 3 | BBB |
METHOTREXATE St. Jude Children's Research Hospital | Phase 3 | BBB |
View all 43 →
Same molecule, other indications
DOXORUBICIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →